What Happened?
San Diego, -based Kura-Oncology Resigned James Basta as Chief Legal Officer, Chief Compliance Officer and Secretary
About the Company
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.
About the Person
James Basta is Executive Vice President, General Counsel and Corporate Secretary at Intellia Therapeutics. Previously, James held various senior legal leadership roles in the industry.
Info Source
News
Short Profile